Last week, PhRMA brought more than 60 member company researchers and scientists to Capitol Hill for a biopharmaceutical researcher fly-in. The fly-in highlighted the important science that’s happening every day at America’s biopharmaceutical research companies aimed at bringing new, innovative medicines to patients in need.
Today, we are on the cusp of a golden era of medical discovery where once the impossible is now possible. While on the Hill, researchers and scientists brought to life the tireless perseverance that can be observed every day inside our member company labs, including the incredible progress being made in the fight against serious diseases. PhRMA members are leading efforts to harness the body’s own immune system to fight cancer, and they were a driving force in the discovery of medicines that have the potential to cure more than 90 percent of patients with hepatitis C. It is also important to note that today, there are more than 7,000 medicines in development worldwide for patients.
America’s biopharmaceutical researchers and scientists are on the frontlines of cutting-edge science bringing new treatments and cures to patients. Their visits with members of Congress further emphasized why it’s critical to advance pro-innovation policies that support America as the leader in biopharmaceutical innovation around the globe.
To learn more about the men and women of America’s biopharmaceutical research companies, visit: http://www.fromhopetocures.org/science
Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.